symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
XBIT,3.9,1.212677,17356,118699230,2.5,3.0-6.69,-0.03,XBiotech Inc.,USD,0001626878,CA98400H1029,98400H102,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.xbiotech.com,"XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.",Mr. John  Simard,Healthcare,US,84,512 386 2900,5217 Winnebago Lane,Austin,TX,78744,6.75803,11.198,https://financialmodelingprep.com/image-stock/XBIT.png,2015-04-15,False,False,True,False,False
